|
Age
|
59 [55–64]
|
58 [55–62]
|
60 [53–67]
|
0.694
|
|
Sex (male), n (%)
|
30
|
10
|
20
| |
|
Weight (kg)
|
80 [75–96]
|
90 [85–96]
|
80 [73–95]
|
0.173
|
|
Body mass index (kg/m2)
|
28 [25–31]
|
28 [28–31]
|
28 [24–32]
|
0.521
|
|
Days since onset of symptoms
|
19 [16–31]
|
18 [16–19]
|
25 [15–35]
|
0.045*
|
|
Days since first confirmed swab
|
16 [9–22]
|
12 [9–14]
|
20 [11–32]
|
0.026*
|
|
Days since hospital admission
|
13 [7–21]
|
12 [8–13]
|
19 [7–31]
|
0.115
|
|
Days since ICU admission
|
12 [3–21]
|
12 [8–13]
|
15 [2–31]
|
0.161
|
|
Comorbidities
|
|
Charlson Comorbidity Index
|
1 [1, 2]
|
2 [1, 2]
|
1 [1, 2]
|
0.878
|
|
Hypertension, n (%)
|
14 (40.0)
|
6 (50.0)
|
8 (34.8)
|
0.477
|
|
Diabetes, n (%)
|
6 (17.1)
|
2 (16.7)
|
4 (17.4)
|
> 0.999
|
|
History of pulmonary embolism, n (%)
|
1 (2.9)
|
0 (0.0)
|
1 (4.3)
|
> 0.999
|
|
Chronic obstructive lung disease, n (%)
|
3 (8.6)
|
2 (16.7)
|
1 (4.3)
|
0.266
|
|
Chronic therapy
|
|
Calcium channel blockers, n (%)
|
2 (5.7)
|
1 (8.3)
|
1 (4.3)
|
> 0.999
|
|
Angiotensin II receptor blockers, n (%)
|
4 (11.4)
|
3 (25.0)
|
1 (4.3)
|
> 0.999
|
|
Angiotensin-converting enzyme inhibitors, n (%)
|
3 (8.6)
|
2 (16.7)
|
1 (4.3)
|
0.239
|
|
Oral anticoagulants, n (%)
|
2 (5.7)
|
2 (16.7)
|
0 (0.0)
|
0.098
|
|
Antiplatelet therapy, n (%)
|
5 (14.3)
|
5 (41.7)
|
0 (0.0)
|
0.150
|
|
Steroids in the previous month, n (%)
|
3 (8.6)
|
2 (16.7)
|
1 (4.3)
|
0.239
|
|
Drugs received during ICU stay
|
|
Darunavir/ritonavir, n (%)
|
5 (14.3)
|
0 (0.0)
|
5 (21.7)
|
0.150
|
|
Hydroxychloroquine, n (%)
|
24 (68.6)
|
10 (83.3)
|
14 (60.9)
|
0.432
|
|
Remdesivir, n (%)
|
1 (2.9)
|
0 (0.0)
|
1 (4.3)
|
> 0.999
|
|
Tocilizumab, n (%)
|
12 (34.3)
|
5 (41.7)
|
7 (30.4)
|
0.709
|
|
Methylprednisolone, n (%)
|
15 (42.9)
|
6 (50.0)
|
9 (39.1)
|
0.721
|
|
Anticoagulation regimen
|
|
None, n (%)
|
1 (2.9)
|
0 (0.0)
|
1 (4.3)
|
0.098
|
|
Enoxaparin, prophylactic dose, n (%)
|
9 (25.7)
|
6 (50.0)
|
3 (13.0)
|
|
Enoxaparin, therapeutic dose, n (%)
|
18 (51.4)
|
5 (41.7)
|
13 (56.5)
|
|
Sodium heparin (continuous infusion), n (%)
|
7 (20.0)
|
1 (8.3)
|
6 (26.1)
|
|
Blood analyses
|
|
Interleukin-6 (ng/L)
|
45 [8–153]
|
18 [8–45]
|
85 [10–739]
|
0.115
|
|
D-dimer (mcg/L)
|
1497 [990–4126]
|
1024 [519–2792]
|
1581 [1174–5358]
|
0.023*
|
|
Ferritin (mcg/L)
|
921 [603–1888]
|
733 [477–904]
|
1399 [888–1929]
|
0.016*
|
|
C-reactive protein (mg/L)
|
17 [9–89]
|
10 [5–16]
|
40 [13–107]
|
0.017*
|
|
Gas exchange
|
|
pHa
|
7.43 [7.40–7.45]
|
7.44 [7.42–7.47]
|
7.43 [7.34–7.45]
|
0.184
|
|
PaCO2 (mmHg)
|
43 [39–53]
|
39 [37–42]
|
47 [42–55]
|
0.001*
|
|
PaO2 (mmHg)
|
94 [77–125]
|
108 [93–144]
|
82 [71–97]
|
0.023*
|
|
PaO2/FiO2 (mmHg)
|
179 [117–195]
|
194 [186–250]
|
139 [108–188]
|
0.002*
|
|
Bicarbonate (mEq/L)
|
28 [25–31]
|
27 [25–28]
|
29 [25–33]
|
0.071
|
|
Respiratory parameters
| | | | |
|
PEEP (cmH2O)
|
10 [8–10]
|
10 [8–10]
|
10 [8–12]
|
0.959
|
|
FiO2 (%)
|
60 [50–70]
|
60 [45–63]
|
60 [50–70]
|
0.172
|
|
Respiratory rate (min−1)
|
19 [16–24]
|
16 [14–20]
|
20 [16–25]
|
0.011*
|
|
Tidal volume per predicted body weight (mL/kg)
|
7.3 [5.5–7.8]
|
n.a
|
7.3 [5.5–7.8]
|
n.a
|
|
Driving pressure (cmH2O)
|
16 [12–18]
|
n.a
|
16 [12–18]
|
n.a
|
|
Plateau pressure (cmH2O)
|
25 [21–28]
|
n.a
|
25 [21–28]
|
n.a
|
|
Compliance (mL/cmH2O)
|
34 [22–43]
|
n.a
|
34 [22–43]
|
n.a
|
|
Ventilatory ratio
|
1.8 [1.4–2.4]
|
n.a
|
1.8 [1.4–2.4]
|
n.a
|
